New One-Piece Injection-Molded COVID-19 Swab to Enable Expanded Testing
By HospiMedica International staff writers Posted on 29 Jun 2020 |
Image: The Hoowaki NP Collection Swab (Photo courtesy of Hoowaki LLC)
An innovative one-piece injection molded design for a COVID-19 swab could help close the gap in US and global COVID-19 testing supplies.
The Hoowaki NP Collection Swab has been developed by Hoowaki LLC (Greenville, SC, USA) using its proprietary HOOWAKI MICROGRIP surface technology to create micro-pillars. The swab met existing industry-standard products for flexibility and performance in clinical user testing and has also proven to be equivalent to the industry-standard flocked filament swabs in the collection of patient RNA that is critical for COVID-19 testing in independent laboratory testing (qPCR Assay). Mass-production of the FDA registered, patent pending, Hoowaki NP Collection Swab will begin this summer and is expected to reach at least several million units per month.
The proprietary Hoowaki NP Collection Swab is manufactured using advanced injection molding technologies that utilize existing equipment that is readily available in communities throughout the world. The swab's scalability is due to Hoowaki LLC's formulations and engineering designs working at existing injection molding facilities, which enables the swab to be produced in quantities that meet local demands anywhere in the world.
"The Hoowaki NP Collection Swab is an important answer to the challenges posed by the global COVID-19 pandemic," said Ralph Hulseman, president of Hoowaki LLC. "Our design allows for production to be quickly scaled in communities around the world—rapidly addressing the rising demand for swabs, a critically important element of all COVID-19 testing."
Related Links:
Hoowaki LLC
The Hoowaki NP Collection Swab has been developed by Hoowaki LLC (Greenville, SC, USA) using its proprietary HOOWAKI MICROGRIP surface technology to create micro-pillars. The swab met existing industry-standard products for flexibility and performance in clinical user testing and has also proven to be equivalent to the industry-standard flocked filament swabs in the collection of patient RNA that is critical for COVID-19 testing in independent laboratory testing (qPCR Assay). Mass-production of the FDA registered, patent pending, Hoowaki NP Collection Swab will begin this summer and is expected to reach at least several million units per month.
The proprietary Hoowaki NP Collection Swab is manufactured using advanced injection molding technologies that utilize existing equipment that is readily available in communities throughout the world. The swab's scalability is due to Hoowaki LLC's formulations and engineering designs working at existing injection molding facilities, which enables the swab to be produced in quantities that meet local demands anywhere in the world.
"The Hoowaki NP Collection Swab is an important answer to the challenges posed by the global COVID-19 pandemic," said Ralph Hulseman, president of Hoowaki LLC. "Our design allows for production to be quickly scaled in communities around the world—rapidly addressing the rising demand for swabs, a critically important element of all COVID-19 testing."
Related Links:
Hoowaki LLC
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans